Journal of Neurodegenerative Diseases / 2013 / Article / Tab 3

Clinical Study

The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease

Table 3

Changes from baseline in neuropsychological measures after 8 months (V2) and 16 months of followup (V3) in patients of groups A and B.

Change in Score from Baseline
8 months16 months
AD with T2-DM
Group A 
AD without T2-DM
Group B 
P AD with T2-DM
Group A
AD without T2-DM
Group B

MMSE .001
MMSE ( ; %)
 (i) Improvement26; 4313; 20.00126; 4315; 23.003
 (ii) Unchanged12; 3822; 34.00315; 2424; 37.001
 (iii) Worsening12; 2030; 46.00120; 3326; 40.05
  ADAS-Cog original; M (SD)0.17 (3.4)0.95 (3.8).0012.2 (4.9)2.9 (5.4).05
  ADAS-Cog modified; M (SD)−0.59 (4.7)0.27 (4.9).0011.9 (5.7)2.5 (6.9).002
CIBIC-Plus Category ( ; %)
 (i) Improvement24; 3920; 31.0529; 4721; 32.001
 (ii) Unchanged16; 2621; 32.0511; 1815; 23.09
 (iii) Worsening21; 3424; 37.2221; 3429; 45.08
CDR sum; M (SD) 0.50 (1.2)0.75 (1.46).091.5 (1.7)1.67 (2.2).39
ADFACS; M (SD)0.53 (0.38)1.56 (0.42).0020.37 (0.4)1.6 (0.4).002
IADL; M (SD)0.87 (0.32)0.13 (0.27).0020.9 (0.37)0.03 (0.3).001

ADAS-Cog: Alzheimer's Disease Assessment Scale, cognitive subscale; CIBIS: Clinician's Interview-Based Impression of Severity; CDR: Clinical Dementia rating; ADFACS: Alzheimer's Disease Functional and Change Scale; ADL: Activities of Daily Living. Values are expressed as mean standard deviation (SD) unless otherwise indicated.
Value of 0.05 was considered statistically significant, after adjusting for confounding variables (sex, serum lipid, triglycerides, BMI, WC, HOMA value, ischemic heart disease, and hypertension).